Zacks downgraded shares of Idera Pharmaceuticals (NASDAQ:IDRA) to a neutral rating in a report issued on Thursday, AnalystRatings.NETreports. They currently have $6.10 target price on the stock. Idera Pharmaceuticals Inc (NASDAQ:IDRA) stock opened at $5.62 in last session, and closed at $5.78, while the day range of stock is $5.25 – $5.85. The stock showed a negative weekly performance of -0.17%.
Northwest Biotherapeutics Inc (NASDAQ:NWBO) a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced, in response to shareholder inquiries, that the Data Safety Monitoring Board (DSMB) has made an unblinded review of the safety data for the Company’s ongoing international Phase III GBM Trial, and has recommended that the trial continue as planned. Northwest Biotherapeutics, Inc (NASDAQ:NWBO) stock opened at $6.44, in last session and closed at $6.06, by gaining 1.68%. The 52 week range of the stock is $3.10 – $7.92. Company’s market capitalization is $263.03 million.
Ophthotech Corp (NASDAQ:OPHT) announced its earnings results on Thursday. The company reported ($0.65) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.50) by $0.15,AnalystRatings.Net reports. Ophthotech Corp (NASDAQ:OPHT) stock decreased -3.37% and finished the last session at $36.96. The EPS of the stock remained -23.31. Company’s market capitalization is $1.16 billion.
Repros Therapeutics Inc (NASDAQ:RPRX) was downgraded by Zacks from an “outperform” rating to a “neutral” rating in a note issued to investors on Tuesday, Analyst Ratings Network.com reports. Repros Therapeutics Inc (NASDAQ:RPRX) stock opened the session at $19.98, and closed the session at $19.30. The 52 week range of the stock remained $8.42 – $29.79 and the day range was $18.56 – $20.72.